OXALIPLATIN INJECTION, USP DIN 02458403
Health Canada record
| Active ingredient(s) | OXALIPLATIN 5 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01XA03 OXALIPLATIN |
| Original market date | 13-Jul-2022 |
| Current status date | 13-Jul-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Dr Reddy's Laboratories (UK) Limited — licence , not currently licensed, last inspection rating C (2019-02-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OXALIPLATIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02444763 | OXALIPLATIN | PFIZER CANADA ULC | Solution | OXALIPLATIN 5 MG | Marketed |
| 02536757 | OXALIPLATIN INJECTION | EUGIA PHARMA INC. | Solution | OXALIPLATIN 5 MG | Approved |
| 02435071 | OXALIPLATIN INJECTION | TEVA CANADA LIMITED | Solution | OXALIPLATIN 5 MG | Marketed |
| 02436167 | OXALIPLATIN INJECTION | ACCORD HEALTHCARE INC | Solution | OXALIPLATIN 5 MG | Approved |
| 02436957 | OXALIPLATIN INJECTION | SANDOZ CANADA INCORPORATED | Solution | OXALIPLATIN 5 MG | Marketed |
| 02454084 | OXALIPLATIN INJECTION | GENERIC MEDICAL PARTNERS INC | Solution | OXALIPLATIN 5 MG | Approved |
| 02532131 | OXALIPLATIN INJECTION | AURO PHARMA INC | Solution | OXALIPLATIN 5 MG | Approved |
| 02433206 | OXALIPLATIN INJECTION USP | STRIDES PHARMA CANADA INC | Solution | OXALIPLATIN 5 MG | Approved |
| 02457423 | OXALIPLATIN INJECTION, USP | FRESENIUS KABI CANADA LTD | Solution | OXALIPLATIN 5 MG | Marketed |
| 02430525 | ACT OXALIPLATIN | ACTAVIS PHARMA COMPANY | Powder For Solution | OXALIPLATIN 50 MG | Cancelled Pre Market |
| 02430533 | ACT OXALIPLATIN | ACTAVIS PHARMA COMPANY | Powder For Solution | OXALIPLATIN 100 MG | Cancelled Pre Market |
| 02432617 | ACT OXALIPLATIN | ACTAVIS PHARMA COMPANY | Solution | OXALIPLATIN 5 MG | Cancelled Post Market |
| 02296276 | ELOXATIN | SANOFI-AVENTIS CANADA INC | Powder For Solution | OXALIPLATIN 100 MG | Cancelled Post Market |
| 02296268 | ELOXATIN | SANOFI-AVENTIS CANADA INC | Powder For Solution | OXALIPLATIN 50 MG | Cancelled Post Market |
| 02296284 | ELOXATIN | SANOFI-AVENTIS CANADA INC | Solution | OXALIPLATIN 5 MG | Cancelled Post Market |
| 02413833 | OXALIPLATIN FOR INJECTION | HOSPIRA HEALTHCARE ULC | Powder For Solution | OXALIPLATIN 50 MG | Cancelled Pre Market |
| 02413841 | OXALIPLATIN FOR INJECTION | HOSPIRA HEALTHCARE ULC | Powder For Solution | OXALIPLATIN 100 MG | Cancelled Pre Market |
| 02431688 | OXALIPLATIN INJECTION | HOSPIRA HEALTHCARE ULC | Solution | OXALIPLATIN 5 MG | Cancelled Pre Market |
| 02437074 | PMS-OXALIPLATIN | PHARMASCIENCE INC | Solution | OXALIPLATIN 5 MG | Cancelled Post Market |
| 02449692 | TARO-OXALIPLATIN | TARO PHARMACEUTICALS INC | Solution | OXALIPLATIN 5 MG | Cancelled Post Market |
| 02446227 | TEVA-OXALIPLATIN INJECTION | TEVA CANADA LIMITED | Solution | OXALIPLATIN 5 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18576 | 2016-10-17 | Abbreviated New Drug Submission (ANDS) |
International API supply for OXALIPLATIN
12 valid EDQM Certificates of Suitability from 12 holders. 17 active FDA Drug Master Files.
Request a quote for OXALIPLATIN INJECTION, USP